SANDOZ News & Analysis
2 articles
Market Mood
Sandoz Receives Canada Approval for Generic Ozempic
Sandoz has received approval from Canadian health authorities to launch a generic version of the diabetes drug Ozempic. This approval may impact the competitive landscape for diabetes treatments in Canada. The generic version could lead to lower prices and increased accessibility for patients. This development is significant for ordinary investors as it may alter revenue dynamics in the pharmaceutical sector due to potentially reduced costs for consumers and increased market competition for Sandoz.
Read More: Sandoz Receives Canada Approval for Generic Ozempic
Sandoz Collaboration with Henlius Worth Up to $322M for Biosimilars
Sandoz has signed a collaboration agreement with Shanghai Henlius Biotech for up to $322 million to develop new biosimilars. This deal includes near-term payments of up to $100.5 million for initial assets and covers up to 10 biosimilars, including those referencing Erbitux, Repatha, and Benlysta. Sandoz, recognized as the largest biosimilar and generics company, increases its biosimilar pipeline from 39 to potentially 46 assets. This partnership occurs against a backdrop of significant opportunities in the industry, coinciding with a large patent cliff projected to drop patent-protected drug sales from 12% in 2022 to 4% by 2030. This matters for investors as the collaboration aims to capture significant market opportunities in biosimilars.
Read More: Sandoz Collaboration with Henlius Worth Up to $322M for Biosimilars